<div id="readability-page-1"><p>H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Vor Biopharma today and set a price target of $32.00.</p><h3>TipRanks Black Friday Sale</h3><ul><li> Claim 60% off TipRanks Premium  for the data-backed insights and research tools you need to invest with confidence.  </li><li>  Subscribe to TipRanks' Smart Investor Picks  and see our data in action through our high-performing model portfolio - <u> now also 60% off </u></li></ul> <p>According to TipRanks, Ramakanth is a 5-star analyst with an average return of <span>17.9%</span> and a 43.00% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics, Personalis, and Evaxion Biotech.</p> <p>Currently, the analyst consensus on Vor Biopharma is a Strong Buy with an average price target of $50.33.</p></div>

<p>H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating for Vor Biopharma with a price target of $32.00. Ramakanth, a 5-star analyst with a 17.9% average return, focuses on healthcare stocks. The consensus on Vor Biopharma is a Strong Buy with an average price target of $50.33.</p>

H.C. Wainwright Sticks to Its Buy Rating for Vor Biopharma (VOR)